서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 121 to 180 of 194

Issue DateTitle / Author(s) / CitationFileAltmetrics
2017-11
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
DOI
2018-01
Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor
view fileDOI
2018-02
Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection
DOI
2018-03
Efficacy of pemetrexed-based chemotherapy in comparison to non-pemetrexed-based chemotherapy in advanced, ALK plus non-small cell lung cancer
view fileDOI
2018-03
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
DOI
2018-06
Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer

Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog

Thoracic Cancer, Vol.9 No.6, pp.736-744

view fileDOI
2018-07
The effect of hospice consultation on aggressive treatment of lung cancer

Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog

Cancer Research and Treatment, Vol.50 No.3, pp.720-728

view fileDOI
2018-07
Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors
DOI
2018-08
Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity
DOI
2019
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
DOI
2019-01
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
DOI
2019-01
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
view fileDOI
2019-01
The risk of herpes zoster in patients with non-small cell lung cancer according to chemotherapy regimens: Tyrosine kinase inhibitors versus cytotoxic chemotherapy

Choi, Ji Young; Kim, Miso; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog; Jo, Seong Jin

Cancer Research and Treatment, Vol.51 No.1, pp.169-177

view fileDOI
2019-01
Significance of 18F-FDG PET parameters according to histologic subtype in the treatment outcome of stage III non–small-cell lung cancer undergoing definitive concurrent chemoradiotherapy
DOI
2019-06
NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors
DOI
2019-07
Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib

Kim, Seulki; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Alm, Yong-Oon; Keam, Bhumsuk; Heo, Dae Seog

Cancer Research and Treatment, Vol.51 No.3, pp.951-962

view fileDOI
2019-07
Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
view fileDOI
2019-07
Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer
view fileDOI
2019-07
Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer

Choi, Mihong; Keam, Bhumsuk; Ock, Chan-Young; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog

Clinical Lung Cancer, Vol.20 No.4, pp.E442-E451

DOI
2019-08
Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study
DOI
2019-09
First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis
DOI
2019-09
Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Ock, Chan-Young; Yoo, Shin-Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Jeon, Yoon Kyung; Kim, Dong Wan; Chung, Doo Hyun; Heo, Dae Seog

The Korean Journal of Internal Medicine, Vol.34 No.5, pp.1116-1124

view fileDOI
2019-09
Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations

Lee, Yusoo; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Keam, Bhumsuk; Ku, Ja-Lok; Heo, Dae Seog

Journal of Thoracic Oncology, Vol.14 No.9, pp.1556-1566

DOI
2019-10
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
DOI
2019-11
Poor prognostic factors in human papillomavirus-positive head and neck cancer: who might not be candidates for de-escalation treatment?
view fileDOI
2019-11
Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
DOI
2019-11
The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer
view fileDOI
2019-11
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer
view filelink
2019-11
ETV2/ER71 regulates the generation of FLK1+ cells from mouse embryonic stem cells through miR-126-MAPK signaling
view filelink
2019-12
8-OxoG in GC-rich Sp1 binding sites enhances gene transcription in adipose tissue of juvenile mice
DOI
2020
Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
view fileDOI
2020
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma
view fileDOI
2020-01
Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non-small cell lung cancer
DOI
2020-02
Hepatoprotective effect of a novel lactic acid-fermented garlic extract functional food product against acute liver injury

Kim, Tae Min; Kim, Ki Hoon; Jo, Jeong Hyun; Park, Joonghoon; Kwon, Yong Sam; Yang, Je Hoon

Food Science and Nutrition, Vol.8 No.2, pp.1012-1019

DOI
2020-02
Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study
DOI
2020-03
Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
view fileDOI
2020-07
A newly developed capture-based sequencing panel for genomic assay of lung cancer
DOI
2020-07
A newly developed capture-based sequencing panel for genomic assay of lung cancer
DOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2020-11
Immunophenotypic landscape and prognosis of diffuse large B-cell lymphoma with MYC/BCL2 double expression: An analysis of a prospectively immunoprofiled cohort
DOI
2020-12
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07
DOI
2020-12
Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells
DOI
2021-01
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
DOI
2021-02
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
DOI
2021-03
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
DOI
2021-04
Cellhesion VP enhances the immunomodulating potential of human mesenchymal stem cell-derived extracellular vesicles
DOI
2021-04
Mesenchymal Stem Cell-derived Extracellular Vesicles for Skin Wound Healing

Kim, Soo; Park, Joonghoon; Kim, Tae Min

Advances in Experimental Medicine and Biology, Vol.1310, pp.495-507

DOI
2021-06
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
DOI
2021-06
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues
DOI
2021-07
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
DOI
2021-08
A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
2021-10
Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma Who Received Systemic Treatment
DOI
2021-10
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

Oh, So Yeon; Kim, Soyeon; Keam, Bhumsuk; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog

Scientific Reports, Vol.11 No.1, p. 19712

2021-11
Cargo proteins in extracellular vesicles: potential for novel therapeutics in non-alcoholic steatohepatitis

Kim, Jimin; Lee, Seul Ki; Jeong, Seon-Yeong; Cho, Hye Jin; Park, Joonghoon; Kim, Tae Min; Kim, Soo

Journal of Nanobiotechnology, Vol.19 No.1, p. 372

DOI
2021-11
EVORPACEPT (ALX148), A CD47 MYELOID CHECKPOINT INHIBITOR, IN PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) AND WITH GASTRIC/GASTROESOPHAGEAL CANCER (GC); ASPEN-01
DOI
2021-11
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFR(T790M)-Mutant NSCLC
DOI
2021-11
Cargo proteins in extracellular vesicles: potential for novel therapeutics in non-alcoholic steatohepatitis

Kim, Jimin; Lee, Seul Ki; Jeong, Seon-Yeong; Cho, Hye Jin; Park, Joonghoon; Kim, Tae Min; Kim, Soo

Journal of Nanobiotechnology. 2021 Nov 17;19(1):372

view fileDOI
2022-01
Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
DOI
2022-04
Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types
DOI
2022-05
Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab
DOI
1 2 3 4